CA-TALKDESK
3.6.2024 15:01:26 CEST | Business Wire | Press release
Talkdesk®, Inc., a global provider of artificial intelligence (AI)-powered customer experience (CX) technology that serves enterprises of all sizes, today launched its latest annual Talkdesk Global Contact Center Key Performance Indicator (KPI) Benchmarking report. Announced this week at Customer Contact Week Las Vegas 2024, the report measures five traditional contact center performance metrics and indicates that amid surging inbound call volumes in 2023, AI helps organizations improve speed to answer, maintain service levels, and more.
The proprietary global data—gathered from across a wide range of industries, company sizes, and locations in 2023—is designed to help contact center leaders successfully navigate industry changes, especially the implications of generative AI (GenAI) on contact center operations and CX delivery. Moreover, the report contains six months of data since Talkdesk layered GenAI across the entire contact center platform, including its flagship Talkdesk CX Cloud™ and Industry Experience Clouds.
While Talkdesk has been an AI innovator since 2018, GenAI radically changed the contact center landscape in 2023. The report will help contact center leaders compare their performance against peers and understand how they can best implement AI and GenAI solutions in order to excel in core contact center competencies.
Among the KPI benchmarks’ insight into the performance and opportunities for success in contact centers, key findings include:
As call volumes increase, KPI indicators show AI offers a path to improved speed to answer and service levels.
- Total inbound calls increased 21% to 390 million in 2023 across Talkdesk customers. In a positive outlook for rising AI usage, speed to answer improved significantly – down 13% to an average of 8.7 seconds – and service level improved slightly to 75.61%.
- While recruitment and attrition were challenges in 2023, AI-powered self-service solutions helped handle a portion of the large volumes of calls despite labor shortages. These results indicate that AI is enabling organizations to engage with customers faster.
Human agents remain critical to the contact center.
- The role of the agent is still mission-critical. With inbound call volumes reaching over 390 million and the average talk time hovering around 2 minutes and 50 seconds, the data implies human agents will likely focus on handling more complex issues and customers who would rather have a human resolve their queries than AI.
Industry-specific contact center solutions correlate with higher service levels.
- While the average service level was maintained from 2022 to 2023 (75.4% in 2022 vs. 75.6% in 2023), some industries achieved higher service levels, including retail and consumer goods (RCG) at 78.5%. Organizations that deploy industry-tailored solutions, like Talkdesk Autopilot for Retail, Banking, and Healthcare, can accelerate contact center transformation with AI. The data implies industries can better address vertical-specific CX queries due to these tailored solutions.
To explore more data findings and examples from organizations seeing success today by leveraging AI and automation tools in the contact center – including results of 90%+ service levels – download the 2024 Talkdesk Global Contact Center KPI Benchmarking Report here.
Supporting Quotes
Neville Letzerich, chief marketing officer at Talkdesk, said: “Contact center KPI benchmarking helps center managers determine best practices, critically evaluate their business, and implement changes to be more competitive. Correlations between AI adoption and traditional contact center KPI performance enables decision makers to intelligently invest in technology solutions that meet their goals and ensure they keep pace with industry standards on AI.”
Crendal Kear, senior vice president of Customer Success at Talkdesk, commented: “As contact center managers operate in a radically changing, increasingly competitive landscape, benchmarking KPI data is invaluable to understand how their center operations measure up. Our customers have different goals, but we believe that learning from the collective experience is important as it reveals opportunities to prioritize success that likely wouldn’t surface from internal reflection.”
About Talkdesk
Talkdesk® is on a mission to rid the world of bad customer experience. With our cloud-native, generative AI-powered CX platform, purpose-built industry solutions, and extensible AI offerings, we empower enterprises in the cloud and on-premises to deliver exceptional customer experiences that make them more competitive, grow revenue, reduce costs, and provide operational efficiencies. With specialized workflows and integrations delivered out of the box for our Industry Experience Clouds, Talkdesk accelerates value for our customers faster and more simply than legacy or one-size-fits-all solutions.
Partnering with enterprises globally, we deliver continuous innovation and breakthrough results. Our commitment to reliability and security, paired with our track record of delivering on promises, sets us apart in the industry. Elevate customer experiences, streamline operations, and increase revenue with Talkdesk. Companies that love their customers use Talkdesk.
Talkdesk is a registered trademark of Talkdesk, Inc. All product and company names are trademarks™ or registered® trademarks of their respective holders. Use of them does not imply any affiliation with or endorsement by them.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240603611611/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
